(Q28534997)

English

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

scientific article (publication date: 2013)

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer (English)

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

12

object named as

Sabine Tejpar

0 references

Eric Van Cutsem

2

object named as

Eric Van Cutsem

0 references

object named as

Hans Prenen

9

0 references

Andrea Sartore-Bianchi

object named as

Andrea Sartore-Bianchi

11

0 references

Salvatore Siena

object named as

Salvatore Siena

1

0 references

Josep Tabernero Caturla

object named as

Josep Tabernero

15

0 references

author name string

Mingyu Li

3

0 references

Ulf Jungnelius

4

0 references

Alfredo Romano

5

0 references

Robert Beck

6

0 references

Katia Bencardino

7

0 references

Maria Elena Elez

8

0 references

Mireia Sanchis

10

0 references

Anita Gandhi

13

0 references

Tao Shi

14

0 references

language of work or name

0 references

publication date

2013

0 references

0 references

8

0 references

11

0 references

e62264

0 references

copyright license

Creative Commons Attribution 4.0 International

11 November 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

19 March 2017

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

19 March 2017

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

19 March 2017

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

19 March 2017

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

19 March 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

7 April 2017

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

7 April 2017

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Antibody-based therapy for solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3823943

29 September 2017

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0062264

21 January 2018

Association of FcGRIIa with Graves' disease: a potential role for dysregulated autoantibody clearance in disease onset/progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of lenalidomide in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24244261

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0062264

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2013PLoSO...862264S

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28534997&oldid=2138133813"